Intervju med vd Andreas Bhagwani efter delårsrapporten Q3 2025
23 October, 2025
Intervju med vd Andreas Bhagwani efter delårsrapporten Q3 2025
ABOUT NANOLOGICA
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers.
Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
NLAB Saga®
A NEW GENERATION SILICA FOR PREPARATIVE CHROMATOGRAPHY
NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
Latest News
Nanologica AB (publ) Receives Order of appx. SEK 1 Million In China
22 October, 2025
Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a new distribution partner in China. The order relates to sampling NLAB Saga® to pharmaceutical manufacturers. “This order is a result of our production now being stable. Going forward we will have larger volumes of our silica products, which is why
Nanologica AB (publ) Receives Additional Order of approx. SEK 2,7 Million from Customer in the US
16 October, 2025
Nanologica has received a supplementary order for the company’s silica-based purification media NLAB Saga® from a customer in the US who placed an initial order of approximately SEK 1.3 million in June. The customer is a manufacturer of peptide drugs and the order relates to evaluation of NLAB Saga® on a production scale. In June,
Listen to our team talk about Nlab Saga®
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
Presentation of Nanologica
For more videos presentations of the company and of interim reports, please refer to Investor Relations.
CEO Andreas Bhagwani presents at Redeye Theme Event Tools and Supplies in Life Science September, 2025.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.